Rubius Therapeutics Income Tax

The latest income tax for RUBY is $54M as of December 2022. That compares with $10M in the prior-year period — up 415.4% year over year. Investors often review this figure alongside Rubius Therapeutics's historical trend and sector peers before judging valuation or financial health.

Over the past year, RUBY's income tax moved from $10M to $54M — a 415.4% year-over-year increase. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Rubius Therapeutics's operating scale or balance-sheet position.

A income tax figure of $54M for RUBY is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. Explore the charts below for those layers of context.

After noting RUBY's income tax ($54M), review year-over-year change from $10M, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.

This page's peer comparison chart is the fastest way to stack Rubius Therapeutics's income tax against similar Healthcare names. You can also browse sector and industry screens on Stockcircle for a broader set of Healthcare companies and their key multiples and fundamentals.